Skip NavigationSkip to Content
Return Return to Search Results

Proteogenomic Characterization of Endometrial Carcinoma

  1. Author:
    Dou, Yongchao
    Kawaler, Emily A
    Cui Zhou, Daniel
    Gritsenko, Marina A
    Huang, Chen
    Blumenberg, Lili
    Karpova, Alla
    Petyuk, Vladislav A
    Savage, Sara R
    Satpathy, Shankha
    Liu, Wenke
    Wu, Yige
    Tsai, Chia-Feng
    Wen, Bo
    Li, Zhi
    Cao, Song
    Moon, Jamie
    Shi, Zhiao
    Cornwell, MacIntosh
    Wyczalkowski, Matthew A
    Chu, Rosalie K
    Vasaikar, Suhas
    Zhou, Hua
    Gao, Qingsong
    Moore, Ronald J
    Li, Kai
    Sethuraman, Sunantha
    Monroe, Matthew E
    Zhao, Rui
    Heiman, David
    Krug, Karsten
    Clauser, Karl
    Kothadia, Ramani
    Maruvka, Yosef
    Pico, Alexander R
    Oliphant, Amanda E
    Hoskins, Emily L
    Pugh, Samuel L
    Beecroft, Sean J I
    Adams, David W
    Jarman, Jonathan C
    Kong, Andy
    Chang, Hui-Yin
    Reva, Boris
    Liao, Yuxing
    Rykunov, Dmitry
    Colaprico, Antonio
    Chen, Xi Steven
    Czekanski, Andrzej
    Jedryka, Marcin
    Matkowski, Rafal
    Wiznerowicz, Maciej
    Hiltke, Tara
    Boja, Emily
    Kinsinger, Christopher R
    Mesri, Mehdi
    Robles, Ana I
    Rodriguez, Henry
    Mutch, David
    Fuh, Katherine
    Ellis, Matthew J
    DeLair, Deborah
    Thiagarajan,Mathangi
    Mani, D R
    Getz, Gad
    Noble, Michael
    Nesvizhskii, Alexey I
    Wang, Pei
    Anderson, Matthew L
    Levine, Douglas A
    Smith, Richard D
    Payne, Samuel H
    Ruggles, Kelly V
    Rodland, Karin D
    Ding, Li
    Zhang, Bing
    Liu, Tao
    Fenyö, David

  2. Author Address

    Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA., Institute for Systems Genetics, NYU School of Medicine, New York, NY 10016, USA; Department of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, NY 10016, USA., Department of Medicine and Genetics, Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63110, USA; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO 63108, USA., Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA., Department of Medicine, NYU School of Medicine, New York, NY 10016, USA., The Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA., Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158, USA., Department of Biology, Brigham Young University, Provo, UT 84602, USA., Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA., Department of Genetics and Genomic Sciences, Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA; Division of Biostatistics, Department of Public Health Science, University of Miami Miller School of Medicine, Miami, FL 33136, USA., Department of Oncology, Wroclaw Medical University, 50-367 Wroclaw, Poland; Wroclaw Comprehensive Cancer Center, 53-413 Wroclaw, Poland., Poznan University of Medical Sciences, 61-701 Poznan, Poland; University Hospital of Lord 39;s Transfiguration, 60-569 Poznan, Poland; International Institute for Molecular Oncology, 60-203 Poznan, Poland., Office of Cancer Clinical Proteomics Research, National Cancer Institute, Bethesda, MD 20892, USA., Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO 63110, USA., Department of Pathology, NYU Langone Health, New York, NY 10016, USA., Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA., Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA., College of Medicine Obstetrics & Gynecology, University of South Florida Health, Tampa, FL 33620, USA., Gynecologic Oncology, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY 10016, USA., Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA; Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University, Portland, OR 97221, USA. Electronic address: karin.rodland@pnnl.gov., Department of Medicine and Genetics, Siteman Cancer Center, Washington University in St. Louis, St. Louis, MO 63110, USA; McDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO 63108, USA. Electronic address: lding@wustl.edu., Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address: bing.zhang@bcm.edu., Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA. Electronic address: tao.liu@pnnl.gov., Institute for Systems Genetics, NYU School of Medicine, New York, NY 10016, USA; Department of Biochemistry and Molecular Pharmacology, NYU School of Medicine, New York, NY 10016, USA. Electronic address: david@fenyolab.org.,
    1. Year: 2020
    2. Date: Feb 20
    3. Epub Date: 2020 02 11
  2. Journal: Cell
    1. 180
    2. 4
    3. Pages: 729-748.e26
  4. Type of Article: Article
  5. ISSN: 0092-8674
  1. Abstract:

    We undertook a comprehensive proteogenomic characterization of 95 prospectively collected endometrial carcinomas, comprising 83 endometrioid and 12 serous tumors. This analysis revealed possible new consequences of perturbations to the p53 and Wnt/ß-catenin pathways, identified a potential role for circRNAs in the epithelial-mesenchymal transition, and provided new information about proteomic markers of clinical and genomic tumor subgroups, including relationships to known druggable pathways. An extensive genome-wide acetylation survey yielded insights into regulatory mechanisms linking Wnt signaling and histone acetylation. We also characterized aspects of the tumor immune landscape, including immunogenic alterations, neoantigens, common cancer/testis antigens, and the immune microenvironment, all of which can inform immunotherapy decisions. Collectively, our multi-omic analyses provide a valuable resource for researchers and clinicians, identify new molecular associations of potential mechanistic significance in the development of endometrial cancers, and suggest novel approaches for identifying potential therapeutic targets. Copyright © 2020 Elsevier Inc. All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.cell.2020.01.026
  3. PMID: 32059776
  4. View record in Web of Science®
  5. WOS: 000514846600011
  6. PII : S0092-8674(20)30107-0

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel